Tremlett H - Search Results

1

Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.

Lu E, Zhu F, Zhao Y, van der Kop M, Synnes A, Dahlgren L, Sadovnick AD, Traboulsee A, Tremlett H. Lu E, et al. Among authors: tremlett h. CNS Drugs. 2014 May;28(5):475-82. doi: 10.1007/s40263-014-0154-6. CNS Drugs. 2014. PMID: 24643915

2

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

Tremlett HL, Oger J. Tremlett HL, et al. Neurology. 2003 Aug 26;61(4):551-4. doi: 10.1212/01.wnl.0000078885.05053.7d. Neurology. 2003. PMID: 12939437 Review.

3

Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes.

Tremlett HL, Oger J. Tremlett HL, et al. Mult Scler. 2004 Jun;10(3):298-301. doi: 10.1191/1352458504ms1007oa. Mult Scler. 2004. PMID: 15222695

4

Disability progression in multiple sclerosis is slower than previously reported.

Tremlett H, Paty D, Devonshire V. Tremlett H, et al. Neurology. 2006 Jan 24;66(2):172-7. doi: 10.1212/01.wnl.0000194259.90286.fe. Neurology. 2006. PMID: 16434648

5

Does the season or month of birth influence disease progression in multiple sclerosis?

Tremlett HL, Devonshire VA. Tremlett HL, et al. Neuroepidemiology. 2006;26(4):195-8. doi: 10.1159/000092406. Epub 2006 Mar 28. Neuroepidemiology. 2006. PMID: 16567947

6

Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients.

Tremlett H, Seemüller S, Zhao Y, Yoshida EM, Oger JD, Petkau J. Tremlett H, et al. Neurology. 2006 Oct 10;67(7):1291-3. doi: 10.1212/01.wnl.0000238515.27055.62. Neurology. 2006. PMID: 17030771 Clinical Trial.

7

Longitudinal follow-up of "benign" multiple sclerosis at 20 years.

Sayao AL, Devonshire V, Tremlett H. Sayao AL, et al. Among authors: tremlett h. Neurology. 2007 Feb 13;68(7):496-500. doi: 10.1212/01.wnl.0000253185.03943.66. Neurology. 2007. PMID: 17296915

8

Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective.

Tremlett HL, Oger J. Tremlett HL, et al. Mult Scler. 2008 Jan;14(1):94-105. doi: 10.1177/1352458507079658. Epub 2007 Sep 19. Mult Scler. 2008. PMID: 17881392

9

Natural history of secondary-progressive multiple sclerosis.

Tremlett H, Yinshan Zhao, Devonshire V. Tremlett H, et al. Mult Scler. 2008 Apr;14(3):314-24. doi: 10.1177/1352458507084264. Epub 2008 Jan 21. Mult Scler. 2008. PMID: 18208898

10

Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.

Tremlett H, Van der Mei I, Pittas F, Blizzard L, Paley G, Dwyer T, Taylor B, Ponsonby AL. Tremlett H, et al. Pharmacoepidemiol Drug Saf. 2008 Jun;17(6):565-76. doi: 10.1002/pds.1593. Pharmacoepidemiol Drug Saf. 2008. PMID: 18395883

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters